Alaunos Therapeutics
TCRT
50 hedge funds and large institutions have $1.69M invested in Alaunos Therapeutics in 2024 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 5 increasing their positions, 11 reducing their positions, and 6 closing their positions.
2,167% more call options, than puts
Call options by funds: $68K | Put options by funds: $3K
83% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 6
11% more funds holding
Funds holding: 45 → 50 (+5)
0.04% more ownership
Funds ownership: 1.46% → 1.51% (+0.04%)
55% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 11
60% less capital invested
Capital invested by funds: $4.23M → $1.69M (-$2.54M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$46.1K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$20.2K |
| 3 |
PI
PFG Investments
Woodbury,
New York
|
+$19.3K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$15.7K |
| 5 |
HF
HRT Financial
New York
|
+$12.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
-$28K |
| 2 |
MCA
Magnolia Capital Advisors
Jackson,
Mississippi
|
-$27.7K |
| 3 |
Osaic Holdings
Scottsdale,
Arizona
|
-$11.1K |
| 4 |
FDCDDQ
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
|
-$5.56K |
| 5 |
Wells Fargo
San Francisco,
California
|
-$3.26K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
HI
51
Harbour Investments
Madison,
Wisconsin
| – | -$843 | -47 | Closed |
|
|
NS
52
NBC Securities
Birmingham,
Alabama
| – | -$1K | -20 | Closed |
|
|
SIS
53
Sound Income Strategies
Ft Lauderdale,
Florida
| – | -$87 | -5 | Closed |
|
|
CTC
54
Central Trust Company
Jefferson City,
Missouri
| – | -$19 | -1 | Closed |
|
|
TC
55
Truvestments Capital
Sarasota,
Florida
| – | -$2 | – | – |
|
56
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | +$358 | +30 | +600% |
|
TCRT Hedge Fund Activity: Q2 2024 in Review
50 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Alaunos Therapeutics (TCRT) for Q2 2024, worth a combined $1.69M — down 60% from $4.23M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new TCRT positions and 6 closed out — a net gain of 5 holders — while 5 added to existing stakes and 11 trimmed.
The largest buyer was UBS Group, adding an estimated $46.1K. The largest seller was Virtu Financial, exiting entirely with an estimated $28K sold.
- 50 institutional investors held Alaunos Therapeutics (TCRT) as of Q2 2024, up from 45 in Q1 2024.
- Funds reported $1.69M of Alaunos Therapeutics stock for Q2 2024, down 60% quarter-over-quarter.
- 11 funds opened new Alaunos Therapeutics positions in Q2 2024 and 6 closed out, a net change of +5 holders.
- The largest Alaunos Therapeutics buyer in Q2 2024 was UBS Group, an estimated $46.1K added.
- The largest Alaunos Therapeutics seller in Q2 2024 was Virtu Financial, an estimated $28K sold.
Based on aggregated 13F filings for Q2 2024.